Zytoprotec is developing drugs using a novel therapeutic approach cytoprotection.

Zytoprotecs lead product, PD-protec®, is a novel peritoneal dialysis fluid including a cytoprotective compound.

In late 2016, the product successfully completed a randomized, double-blinded Phase II study with outstanding results.

Worldwide, 2.7 million patients annually receive dialysis treatment. About 11 percent of these patients are treated with peritoneal dialysis (PD).

Cytoprotective PD solutions have the potential to significantly improve the outcomes of PD treatment and consequently to increase the share of PD within the overall dialysis market.